A model in which H3K79me2 contributes to alternative splicing regulation in MLLr AML is supported, linking the core epigenetic lesion of this disease to aberrant RNA processing with potential prognostic relevance.
Abstract
Background/Objectives: Aberrant H3K79 dimethylation (H3K79me2) by DOT1L is a defining feature of MLL-rearranged (MLLr) acute myeloid leukemia (AML), but whether this modification influences alternative splicing is unclear. We examined the relationship between H3K79me2 and exon skipping in primary MLLr AML. Methods: We performed H3K79me2 ChIP-seq and RNA-seq on primary samples from 24 MLLr AML patients, 4 wild-type MLL AML patients, and 4 healthy bone marrow donors, with matched profiling before and after DOT1L inhibition using EPZ5676. DOT1L co-immunoprecipitation with mass spectrometry (IP-MS) was performed in MV-4-11 and MOLM-14 cells, and an aggregate splicing score was evaluated in the TCGA-AML cohort. Results: A subset of exon skipping (SE) events was enriched at H3K79me2-occupied loci in MLLr samples. EPZ5676 remodeled SE patterns, and many switched events showed concurrent loss of local H3K79me2. Genes harboring these events were enriched for RNA processing, DNA repair, and apoptosis functions. Core spliceosomal and hnRNP proteins were prominent in the DOT1L interactome and were reduced after EPZ5676, and SRSF2 and hnRNPA1 binding motifs were enriched near the regulated exons. About two-thirds of the common switched events overlapped a local H3K79me2 peak, and an aggregate splicing score derived from these events stratified patients by overall survival in the TCGA-AML cohort, with higher scores associated with shorter survival. Conclusions: These data support a model in which H3K79me2 contributes to alternative splicing regulation in MLLr AML, linking the core epigenetic lesion of this disease to aberrant RNA processing with potential prognostic relevance.
EIF4A3-dependent NMD is defined as a checkpoint linking RNA surveillance to oncogenic fusion-isoform dosage, leukemic fitness, and chemosensitivity in t(8;21) AML, providing a mechanistic explanation for clinical heterogeneity in t(8;21) AML.
Min Zhang, Yisheng Li, Bin Zhang et al.· Leukemia· 1 citation
SDRNAs are introduced as standalone regulatory effector molecules in healthy hematopoiesis and AML and proposed and characterized NUDT21, an important regulator of alternative polyadenylation and oncogenic gene expression, as a downstream target of sd3'-SNORD78 in AML.
R. Zinz, Christian Rohde, C. Pauli et al.· Leukemia· 0 citations
BACKGROUND
N6-methyladenosine (m6A) drives T-cell acute lymphoblastic leukemia (T-ALL); however, its roles in leukemic heterogeneity and tumor microenvironment remodeling unclear. This study characterized N6-methyladenosine regulator-defined subpopulations and YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) in le...
Chao Liu, Wei-Min Wang, Fang Wang et al.· Chinese Medical Journal· 0 citations
Findings implicate MBNL1 as a distinct FLT3 activator by recognizing a structured enhancer ssDNA element, highlighting an unexpected role for RNA binding proteins in transcriptional regulation through direct ssDNA recognition.
Meixia Che, Shaela Fields, Siqi Yi et al.· Science Advances· 0 citations
Findings support an association between DHX15, HNRNPL, RBM33 and AE9a splicing and suggest their contribution to leukemogenic progression in AE+ AML and three‐dimensional structure prediction suggests a sophisticated regulatory complex formation.
Qiao Liu, Xuechun Wang, Jiqiang Fan et al.· British Journal of Haematolo...· 0 citations
SetDB1 is best known for catalyzing H3K9me3, but it also influences H3K27me3 deposition, CTCF-binding, and DNA methylation (DNAme). Given the interplay between DNAme and the other epigenetic features, we profiled DNAme following Setdb1 knockout (KO) in ground-state and serum-grown mouse embryonic stem cells (ESCs) to i...
Nick G. P. Bovee, E. Habibi, Zi-Cong Liu et al.· Stem Cell Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.